

**NEW YORK STATE MEDICAID
PREFERRED DRUG PROGRAM
2012 THERAPEUTIC CLASS RE-REVIEW**

The New York Medicaid Pharmacy & Therapeutics (P&T) Committee will re-review the following Preferred Drug Program (PDP) therapeutic classes in 2012 (see table below) as new relevant clinical and/or financial information, since the previous review of the class, is known to exist. P&T Committee meeting agendas for 2012 are under development and will be posted on the Department of Health (DoH) web-site thirty (30) days prior to the meeting date.

2012 PDP Re-Review

Therapeutic Category	Therapeutic Classes	Previous Review Date
Analgesic	Prescription Non-Steroidal Anti-inflammatory Drugs	September 16, 2010
	Long Acting Opioids	June 16, 2011
	Short Acting Opioids	June 16, 2011
Anti-Infective	Injectable Hepatitis C Agents	September 16, 2010
	Oral Antivirals	September 11, 2009
Cardiovascular	Direct Renin Inhibitors	April 15, 2011
	HMG-CoA Reductase Inhibitors/Statins	April 15, 2011
	Triglyceride Lowering Agents	April 15, 2011
Central Nervous System	Atypical Antipsychotics	June 16, 2011
	Central Nervous System Stimulants	April 15, 2011
	Selective Serotonin Reuptake Inhibitors	June 16, 2011
	Serotonin-Norepinephrine Reuptake Inhibitors	June 16, 2011
Endocrine/Metabolic	Dipeptidyl Peptidase-4 Inhibitors	June 16, 2011
	Glucagon-like Peptide-1 Agonists	June 16, 2011
	Pancreatic Enzymes	June 16, 2011
Gastrointestinal	Anti-Emetics	June 16, 2011
	Sulfasalazine Derivatives	June 16, 2011
Hematological	Platelet Inhibitors	June 11, 2010
Immunologic	Injectable Immunomodulators	April 29, 2010
Ophthalmic	Prostaglandin Agonists	April 15, 2011

Renal/Genitourinary	Phosphate Binders/Regulators	April 29, 2010
	Urinary Tract Antispasmodics	April 15, 2011
Respiratory	Inhaled Anticholinergics	September 16, 2010
	Long Acting Beta2 Adrenergic Agents/LABAs	September 16, 2010
	Leukotriene Modifiers	June 10, 2009

The current preferred and non-preferred status of drugs subject to the PDP may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

At this time, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes since previously reviewed and the DoH proposes no changes to the established Commissioner's final determinations. If interested parties have new relevant clinical information, please submit to the Medicaid Bureau of Pharmacy Policy and Operations (pandtc@health.state.ny.us) in a timely manner. The DoH will consider any new relevant clinical information provided when developing future P&T Committee meeting agendas.

In determining new clinical information, the previous review dates for all therapeutic classes are available on previous meeting agendas which may be viewed at http://www.health.ny.gov/health_care/medicaid/program/ptcommittee/

- New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of re-review and submission is discouraged.
- Those wishing to submit new clinical information may do so as it becomes available. New information is preferred in an electronic format and may be submitted to pandtc@health.state.ny.us (please reference P&T Committee re-review).
- Clinical information submitted in response to a meeting agenda posted on the P&T Committee web-page must be received by the DoH no later than two (2) weeks prior to the meeting date or the Committee may not have ample time to review the information.

Please continue to monitor the DoH web-site for P&T Committee meeting schedules and agendas (http://www.health.ny.gov/health_care/medicaid/program/pharmacy.htm)

Posted: 3/01/2012